[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100466669":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":37,"locations":43,"responsibleParty":139,"collaborators":141,"id":144,"slug":145,"hasResults":146,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":31,"eligibilityCriteria":150,"healthyVolunteers":151,"sex":152,"minAge":153,"maxAge":31,"enrollmentInfo":154,"targetDuration":31,"studyType":157,"phases":158,"briefSummary":161,"conditions":162,"keywords":31,"overallStatus":46,"whyStopped":31,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},{"fullName":5,"class":6},"Vir Biotechnology, Inc.","INDUSTRY",[8,14,19,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1 (dose escalation)","EXPERIMENTAL","Participants will receive single-agent VIR-5818",[13],"Drug: VIR-5818",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 2 (dose escalation)","Participants will receive VIR-5818 plus pembrolizumab",[13,18],"Drug: pembrolizumab",{"label":20,"type":10,"description":11,"interventionNames":21},"Part 3 (dose expansion)",[13],{"label":23,"type":10,"description":16,"interventionNames":24},"Part 4 (dose expansion",[13,18],[26,32],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","VIR-5818","Administered as IV infusion",[9,15,20,23],null,{"type":27,"name":33,"description":29,"armGroupLabels":34,"otherNames":35},"pembrolizumab",[15,23],[36],"KEYTRUDA®",[38],{"name":39,"role":40,"phone":41,"phoneExt":31,"email":42},"Study Inquiry","CONTACT","415-654-5281","clinicaltrials@vir.bio",[44,58,67,78,89,100,106,115,121,130],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":31},"Investigational site number #100","RECRUITING","Melbourne","Victoria","3000","Australia","AU",{"type":53,"coordinates":54},"Point",[55,56],144.96332,-37.814,{"lat":56,"lon":55},{"facility":59,"status":46,"city":60,"state":31,"zip":61,"country":50,"countryCode":51,"cosmosGeoPoint":62,"geoPoint":66,"contacts":31},"Investigational site number #101","Randwick","2031",{"type":53,"coordinates":63},[64,65],151.24895,-33.91439,{"lat":65,"lon":64},{"facility":68,"status":46,"city":69,"state":31,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":77,"contacts":31},"Investigational site number #150","Toulouse","31059","France","FR",{"type":53,"coordinates":74},[75,76],1.44367,43.60426,{"lat":76,"lon":75},{"facility":79,"status":46,"city":80,"state":31,"zip":81,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":88,"contacts":31},"Investigational site number #200","Porto","4200-072","Portugal","PT",{"type":53,"coordinates":85},[86,87],-8.61097,41.1485,{"lat":87,"lon":86},{"facility":90,"status":46,"city":91,"state":31,"zip":92,"country":93,"countryCode":94,"cosmosGeoPoint":95,"geoPoint":99,"contacts":31},"Investigational site number #255","Barcelona","08023","Spain","ES",{"type":53,"coordinates":96},[97,98],2.15899,41.38879,{"lat":98,"lon":97},{"facility":101,"status":46,"city":91,"state":31,"zip":102,"country":93,"countryCode":94,"cosmosGeoPoint":103,"geoPoint":105,"contacts":31},"Investigational site number #251","08035",{"type":53,"coordinates":104},[97,98],{"lat":98,"lon":97},{"facility":107,"status":46,"city":108,"state":31,"zip":109,"country":93,"countryCode":94,"cosmosGeoPoint":110,"geoPoint":114,"contacts":31},"Investigational site number #254","Madrid","28027",{"type":53,"coordinates":111},[112,113],-3.70256,40.4165,{"lat":113,"lon":112},{"facility":116,"status":46,"city":108,"state":31,"zip":117,"country":93,"countryCode":94,"cosmosGeoPoint":118,"geoPoint":120,"contacts":31},"Investigational site number #252","28050",{"type":53,"coordinates":119},[112,113],{"lat":113,"lon":112},{"facility":122,"status":46,"city":123,"state":31,"zip":124,"country":93,"countryCode":94,"cosmosGeoPoint":125,"geoPoint":129,"contacts":31},"Investigational site number #250","Pamplona","31008",{"type":53,"coordinates":126},[127,128],-1.64323,42.81687,{"lat":128,"lon":127},{"facility":131,"status":46,"city":132,"state":31,"zip":133,"country":93,"countryCode":94,"cosmosGeoPoint":134,"geoPoint":138,"contacts":31},"Investigational site number #253","Pozuelo de Alarcón","28223",{"type":53,"coordinates":135},[136,137],-3.81338,40.43293,{"lat":137,"lon":136},{"type":140,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR",[142],{"name":143,"class":6},"Merck Sharp & Dohme LLC","100466669","phase-1-to-access-the-safety-and-effects-of-intravenous-administration-of-vir-5818-alone-and-in-combination-with-pembrolizumab-in-adult-participants-with-locally-advanced-or-metastatic-her2-expressing-cancers-100466669",false,"NCT05356741","To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers","A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of VIR-5818 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers","Inclusion criteria:\n\n* Written informed consent by the participant (or legally acceptable representative if applicable)\n* Life expectancy of at least 12 weeks\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Diseases under study, prior lines of therapy, and human epidermal growth factor receptor 2 (HER2) status, per local tests\n\nExclusion criteria:\n\n* Significant cardiopulmonary disease and recent cardiac events\n* History of major organ autoimmune diseases\n* Acute or chronic infections\n\nThe above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.",true,"ALL","18 Years",{"count":155,"type":156},645,"ESTIMATED","INTERVENTIONAL",[159,160],"PHASE1","PHASE2","This first-in-human (FIH) Phase 1 open-label multicenter dose-escalation and dose-expansion study is designed to evaluate the safety, pharmacokinetics, and preliminary activity of VIR-5818 (Formerly AMX-818) as a single agent and in combination with pembrolizumab in participants with HER2+ tumors across multiple tumor types. The study will be conducted in four parts:\n\n* Part 1 (dose escalation): Single-agent VIR-5818\n* Part 2 (dose escalation): VIR-5818 plus pembrolizumab\n* Part 3 (dose expansion): Single-agent VIR-5818\n* Part 4 (dose expansion): VIR-5818 plus pembrolizumab\n\nThe total length of the study, from screening of the first participant to the end of the study, is expected to be approximately 52 months.",[163],"Locally Advanced or Metastatic HER2-Expressing Cancers","2025-09-19",{"date":166,"type":167},"2025-09-24","ACTUAL",{"date":169,"type":167},"2022-04-13",{"date":171,"type":156},"2027-08-16",{"name":5,"class":6},10]